HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Beijing Advaccine Biotechnology - Would the “new Force” Become the Terminator of COVID-19?

Chongqing Zhifei Biological Products (300122.CH) - Could Zhifei Support Its Valuation?

CanSino Biologics (6185.HK) - Will the COVID-19 Vaccine Be the Turning Point?

Industry Report - Insights on China Vaccine Industry

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<p>Given the global COVID-19 situation is still not yet optimistic, the vaccine is widely recognized the best solution to end the pandemic. Recently, the inhaled COVID-19 vaccine of <a href="https://www.smartkarma.com/entities/cansino-biologics-inc-cc0c90b7-e854-4ba3-929b-914be1bd0d89" target="_blank" data-smartkarma-citation="entities:32181:1" rel="noopener">CanSino Biologics Inc (688185 CH)</a> (or <a href="https://www.smartkarma.com/entities/cansino-biologics-inc" target="_blank" data-smartkarma-citation="entities:27739:1" rel="noopener">CanSino Biologics Inc (6185 HK)</a>) is applying for emergency use in China, which is currently in phase II clinical trial. At present, the R&amp;D of nasal spray/inhaled COVID-19 vaccines of different companies are actively in process, and CanSino is expected to take the lead in this field and realize the corner overtaking, which worth the attention of investors.</p>

Given the global COVID-19 situation is still not yet optimistic, the vaccine is widely recognized the best solution to end the pandemic. Recently, the inhaled COVID-19 vaccine of CanSino Biologics Inc (688185 CH) (or CanSino Biologics Inc (6185 HK)) is applying for emergency use in China, which is currently in phase II clinical trial. At present, the R&amp;D of nasal spray/inhaled COVID-19 vaccines of different companies are actively in process, and CanSino is expected to take the lead in this field and realize the corner overtaking, which worth the attention of investors.

CanSino Biologics (688185.CH/6185.HK) - Time for Corner Overtaking?